@article{46770c55862943e3a7e36a87f28eb124,
title = "Response to Comment on Dawed et al. Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas. Diabetes Care 2021;44:2673-2682",
author = "Dawed, {Adem Y.} and Yee, {Sook Wah} and Kaixin Zhou and {van Leeuwen}, Nienke and Yanfei Zhang and Siddiqui, {Moneeza K.} and Amy Etheridge and Federico Innocenti and Fei Xu and Li, {Josephine H.} and Beulens, {Joline W.} and {van der Heijden}, {Amber A.} and Slieker, {Roderick C.} and Yu-Chuan Chang and Mercader, {Josep M.} and Varinderpal Kaur and Witte, {John S.} and Lee, {Ming Ta Michael} and Yoichiro Kamatani and Yukihide Momozawa and Michiaki Kubo and Palmer, {Colin N. A.} and Florez, {Jose C.} and Hedderson, {Monique M.} and {'t Hart}, {Leen M.} and Giacomini, {Kathleen M.} and Pearson, {Ewan R.} and {The DIRECT consortium}",
note = "Funding Information: Funding. The work leading to this publication has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement no. 115317 (DIRECT), resources of which are composed of financial contribution from the European Union{\textquoteright}s Seventh Framework Programme (FP7/2007-2013) and European Federation of Pharmaceutical Industries (EFPIA) companies{\textquoteright} in-kind contribution. Funding was in part from the National Institutes of Health (NIH), R01-GM117163, to J.C.F., M.M.H., and K.M.G. E.R.P. holds a Wellcome New Investigator Award (102820/Z/13/Z). Funding for the Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans (SUGAR-MGH) was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, R01-DK088214. J.H.L. is supported by NIDDK, NIH, T32-DK007028. J.C.F. is supported by NIDDK, NIH, K24-DK110550. The Geisinger MyCode type 2 diabetes project was supported by the Geisinger Health Plan Quality Pilot Fund (principal investigator: M.T.M.L.). Duality of Interest. E.R.P. has received honoraria for speaking from Lilly and Sanofi. J.C.F. has received honoraria for speaking at scientific conferences from Novo Nordisk and for consulting from Goldfinch Bio. No other potential conflicts of interest relevant to this article were reported.",
year = "2022",
month = apr,
doi = "10.2337/dci21-0066",
language = "English",
volume = "45",
pages = "e82--e83",
journal = "Diabetes Care",
issn = "0149-5992",
publisher = "American Diabetes Association Inc.",
number = "4",
}
